Mesenchymal stromal cells (MSCs) are a heterogeneous cell population with the ability to reduce inflammation. MSC-derived extracellular vesicles transport these anti-inflammatory properties of the cells. They remain in the bloodstream for a long time and can migrate through the blood-brain barrier and synovial membranes. In addition, they have low cytotoxicity and are well tolerated after transfusion.
The project aims to genetically modify MSCs in such a way that they use the natural packaging mechanism of the cells to release anti-inflammatory cytokines with their extracellular vesicles.